The biotechnology company has received the award for ‘Best New Product for Production Animals of the Year’ for our vaccine DIVENCE® PENTA, registered last year 

HIPRA, the biotechnology pharmaceutical company with more than 50 years of experience in prevention, has received the award for “Best New Product for Production Animals of the Year”, granted by the Animal Health, Nutrition and Technology Innovation forum. The biotechnology company has been recognized for developing DIVENCE® PENTA, a vaccine that enhances prevention strategies against the most relevant viruses affecting livestock worldwide, targeting bovine respiratory syncytial virus (BRSV), bovine viral diarrhea virus (BVDV) types 1 and 2, parainfluenza virus 3 (PI-3), and infectious bovine rhinotracheitis caused by bovine herpesvirus 1 (BoHV-1).

DIVENCE® PENTA is a marker vaccine for the viruses (BVDV-1, BVDV-2 and BoHV-1) enabling the differentiation between infected and vaccinated animals, following the DIVA approach. This innovative tool introduces a new way of working for veterinarians and farmers, facilitating accurate diagnosis and monitoring, as well as better management of vaccination programs. 
 

Marta Gibert, Biologicals R&D Researcher & Project Leader at HIPRA, received the award on behalf of the entire HIPRA team. Gibert highlighted that "this prestigious award underscores the company's commitment to developing biological solutions that optimize the work of veterinarians. These solutions are made possible thanks to the solid scientific and technical expertise of the HIPRA team."

"We are extremely proud to receive this award. Our focus is on prevention, and we make a strong investment in our R&D line to develop new tools that create a real impact on the daily work of veterinarians and farmers, while also improving animal welfare globally. Receiving this recognition motivates us to continue advancing on this path," stated David McGahie, Business Development and Licensing Director at HIPRA.

This recognition highlights HIPRA’s more than 50 years of dedication to the research, production, and commercialization of biological products. As a leader in prevention, the company allocates more than 10% of its annual revenue to R&D, driving the development of innovative solutions to address the current challenges of the sector. 

In a context where global health faces challenges such as the growing antimicrobial resistance and the need to move toward more sustainable livestock production, HIPRA plays a key role. Through its biological products and preventive approach, the company actively contributes to reducing antibiotic use, improving animal welfare, and optimizing production efficiency. Additionally, HIPRA’s contribution aligns perfectly with the One Health approach, which integrates animal, human, and environmental health to comprehensively address global challenges.